Clinical-stage biopharmaceutical company Alzheon has secured $100m in a Series E funding round to develop and commercialise ALZ-801/Valiltramiprosate, an oral tablet designed as a disease-modifying therapy for Alzheimer’s disease (AD).

Alerce Medical Technology Partners spearheaded the financing round.

The development comes after the company raised $50m in a Series D round in 2022.

The investment will be used to complete the APOLLOE4 Phase III clinical trial to evaluate the efficacy of ALZ-801 in 325 early AD patients.

The study will report its results in the third quarter of 2024, with a new drug application (NDA) submission to follow.

ALZ-801 inhibits the formation of soluble toxic amyloid aggregates, acting upstream from all late-stage amyloid-targeting treatments.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The financial boost will also support the manufacture of the product and prepare for the potential launch of ALZ-801 commercially, as the first oral disease-modifying therapy for Alzheimer’s.

ALZ-801 has demonstrated the ability to fully block the formation of neurotoxic soluble beta-amyloid oligomers at the Phase III clinical dose level.

It also demonstrated clinical efficacy in the highest-risk AD population and favourable safety, without causing higher brain vasogenic oedema risk.

ALZ-801 was also evaluated in a two-year, 84-patient, Phase II biomarker study completed in the second half of 2023.

The biomarker trial is now extending into a fourth year.

Alzheon founder, president and CEO Martin Tolar stated: “Alzheon has experienced tremendous progress in the past year and the promise of our novel oral Alzheimer’s treatment, ALZ-801, has attracted prominent institutional and private investors.

“Our ability to raise $150m over the last two financing rounds in the current climate speaks volumes about the prospects of our innovative science and technology.

“Our well-differentiated drug candidate with a favourable safety profile, showing no increased risk of vasogenic brain oedema in more than 3,000 AD patients, is positioned to potentially become the first oral disease-modifying therapy for the treatment of Alzheimer’s disease.”